Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults | Zendy

Rafaëlla FA L'homme | Zendy; Tim Dijkema | Zendy; Adilia Warris | Zendy; André van der Ven | Zendy; Diana M. Gibb | Zendy; David M. Burger | Zendy

Open Access

Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults

Author(s) -

Rafaëlla FA L'homme,

Tim Dijkema,

Adilia Warris,

André van der Ven,

Diana M. Gibb,

David M. Burger

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl445

Subject(s) - stavudine , nevirapine , lamivudine , pharmacokinetics , human immunodeficiency virus (hiv) , medicine , pharmacology , reverse transcriptase inhibitor , virology , sida , viral disease , viral load , antiretroviral therapy , virus , hepatitis b virus

Cipla Pharmaceuticals have developed generic fixed-dose combinations of stavudine, lamivudine and nevirapine for HIV-infected children (Pedimune Baby and Junior). We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research